This article is more than 5 years old. Information may no longer be current.

Zimura-Lucentis combination safe in wet AMD patients in phase 2a trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Zimura, a complement factor C5 inhibitor, was found to be well tolerated in combination with Lucentis in a phase 2a clinical trial, Ophthotech announced in a press release.

Sixty-four patients with wet age-related macular degeneration were enrolled in the randomized, dose-ranging, open-label, multicenter phase 2a safety trial of Zimura (avacincaptad pegol) in combination with Lucentis (ranibizumab, Genentech). The treatment-naive patients were assigned to receive one of four dosing regimens.

“This uncontrolled clinical trial with a small sample size was not designed to detect a statistically significant difference between Zimura dose groups or to evaluate the efficacy of Zimura combination therapy with statistical significance,” Kourous A. Rezaei, MD, Ophthotech chief medical officer, said in the release.

After 6 months of treatment, the Zimura combination therapy was generally well tolerated, and the most frequently reported adverse events were related to the injection procedure, the release said.